Factbox: Drugmakers rush to sign deals on first day of industry conference

Intra-Cellular Therapies

13/01/2025 17:00

Jan 13 (Reuters) - Drugmakers signed deals worth at
least $18 billion in combined value on Monday, the first day of
the healthcare industry's top conference in San Francisco. 
    Dealmakers are anticipating a surge in megadeals worth over
$10 billion, buoyed by hopes of a more lenient antitrust
environment under the incoming Trump administration.
    The following is a list of deals that took place on Monday
ahead of the JPMorgan Healthcare Conference:
    
    GSK-IDRx
    British drugmaker GSK  GSK.L  said that it would pay up to
$1.15 billion to buy Boston-based biopharmaceutical firm IDRx.
    
    J&J-Intra-Cellular Therapies
    Johnson & Johnson  JNJ.N  said it will buy Intra-Cellular
Therapies  ITCI.O  for $14.6 billion, with plans to fund the
deal through a combination of cash and debt.
    
    Eli Lilly-Scorpion Therapeutics
    Eli Lilly  LLY.N  plans to buy Scorpion Therapeutics'
experimental cancer therapy for up to $2.5 billion in cash to
expand its pipeline of cancer treatments.
    
    AbbVie-Simcere Pharmaceutical
    AbbVie  ABBV.N  has obtained the option to license a new
blood cancer drug candidate from Simcere Pharmaceutical's
 2096.HK  unit for markets outside China, in a deal valued at up
to $1.06 billion.

 (Reporting by Kamal Choudhury and Puyaan Singh in Bengaluru;
Editing by Shailesh Kuber)
 ((Kamal.Choudhury@thomsonreuters.com;))